| 摘要 |
The use of SDF-1 for the manufacture of a medicament for the treatment and/or prevention of a neurological disease, wherein said SDF-1 is selected from SDF-1a or a SDF-1a variant or SDF-1_ having an additional N-terminal methionine and wherein the 5 neurological disease is selected from the group consisting of neuropathies, peripheral neuropathy, traumatic nerve injury, demyelinating diseases of the PNS, primary progressive multiple sclerosis (MS), secondary progressive multiple sclerosis (MS), chronic inflammatory demyelinating polyradiculoneuropathy (CIDP) and Guillan-Barré syndrome (GBS). |
